Showing results (261-270 of 270) with videos related to

Sort By:
Pageof 27
You have reached the last page of results.This site can display upto 270 results.
Future Oncology (London, England)|February 2, 2021
Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphomaJatin Shah, Sharon Shacham, Michael Kauffman, et al.
Blood Advances|June 25, 2026
Renoir phase III Rituximab-Lenalidomide vs Rituximab as Maintenance Treatment in Relapsed/Refractory Follicular LymphomaBarbara Botto, Carola Boccomini, Andrea Evangelista, et al.
The Lancet. Haematology|September 20, 2025
Rituximab, bendamustine, and cytarabine followed by venetoclax in older patients with high-risk mantle cell lymphoma (FIL_V-RBAC): a multicentre, single-arm, phase 2 studyCarlo Visco, Valentina Tabanelli, Maria Vittoria Sacchi, et al.
Blood Advances|March 19, 2026
Quantitative MYD88 L265P and flow cytometry levels for outcome determination in IgM gammopathies: the SAL-TO studyIrene Dogliotti, Cristina Jiménez, Veronica Peri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 12, 2021
Simplified Geriatric Assessment in Older Patients With Diffuse Large B-Cell Lymphoma: The Prospective Elderly Project of the Fondazione Italiana LinfomiFrancesco Merli, Stefano Luminari, Alessandra Tucci, et al.
Haematologica|February 22, 2024
IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphomaAnastasios Stathis, Maria Cristina Pirosa, Lorella Orsucci, et al.
The Lancet. Haematology|June 27, 2024
Local radiotherapy and measurable residual disease-driven immunotherapy in patients with early-stage follicular lymphoma (FIL MIRO): final results of a prospective, multicentre, phase 2 trialAlessandro Pulsoni, Simone Ferrero, Maria Elena Tosti, et al.
Blood Advances|July 24, 2026
Molecular biomarkers as key determinants of outcome in mantle cell lymphoma: results from the FIL V-RBAC trialRiccardo Moia, Mohammad Almasri, Maria Elena Carazzolo, et al.
Oncoimmunology|July 3, 2015
Consensus nomenclature for CD8+ T cell phenotypes in cancerLionel Apetoh, Mark J Smyth, Charles G Drake, et al.
Oncotarget|December 25, 2014
Classification of current anticancer immunotherapiesLorenzo Galluzzi, Erika Vacchelli, José-Manuel Bravo-San Pedro, et al.
Pageof 27